Market Movers Today: Switch Inc (SWCH), Longfin Corp (LFIN), Cellectis SA (ADR) (CLLS), Adamas Pharmaceuticals Inc (ADMS), and More

Switch Inc (NYSE:SWCH) (The Motley Fool)
What happened: Shares of Switch (NYSE:SWCH) have gotten crushed today, down by 16% as of 12:20 p.m. EDT, after the data center specialist reported fourth-quarter earnings. Net losses were worse than expected. So what: Revenue in the fourth quarter came in at $99.3 million, which was just slightly shy of the $99.6 million in sales that analysts were modeling for.

Longfin Corp (NASDAQ:LFIN) (Yahoo Finance)
Longfin Corp. (LFIN): Shares are tumbling, down -31%. The blockchain tech firm revealed it is under SEC investigation for failing to disclose important information surrounding its recent IPO and several misstatements the company has made since then.

crystal51/Shutterstock.com

Cellectis SA (ADR) (NASDAQ:CLLS) (Benzinga)
Cellectis S.A. shares climbed 10.6 percent to $34.00. Cellectis and Allogene Therapeutics intends to continue strategic cancer immunotherapy partnership which originally consisted of Pfizer and Cellectis.

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) (Seeking Alpha)
Enrollment is underway in a Phase 3 clinical trial assessing Adamas Pharmaceuticals’ (ADMS +4.2%) GOCOVRI (amantadine) extended-release capsules in multiple sclerosis (MS) patients with walking impairment. The primary endpoint of the 540-subject study is timed 25 foot walk (T25FW) compared to placebo. Two once-daily doses (137 mg and 274 mg) will be evaluated. According to ClinicalTrials.gov, the estimated completion date is September 2019. The FDA approved GOCOVRI in August 2017 for dyskinesia (uncontrolled movements) in Parkinson’s disease patients receiving levodopa-based therapy.